Zhang Chenhao, Zhao Shuqin, Zang Yanjing, Gu Fang, Mao Shufang, Feng Shanshan, Hu Lei, Zhang Chunliang
Department of Neurology, The Second Hospital of Baoding city Department of Internal Medicine, Hospital Affiliated to Hebei University Department of Geriatric, The Second Hospital of Baoding City Fifth Department of Internal Medicine, Baoding Children's Hospital, Baoding Department of Statistical, Chengde Medical Collage, Chengde, Hebei, China.
Medicine (Baltimore). 2017 Jul;96(30):e7257. doi: 10.1097/MD.0000000000007257.
Progressive cerebral infarction (PCI) is associated with high rates of mortality and disability. Many studies have shown that Dl-3n-butylphthalide (NBP) is effective against acute ischemic stroke. The administration of NBP can result in an increased number of capillaries in the ischemic region, promote the establishment of collateral circulation, protect the mitochondria, and narrow the infarction area, among other effects. In the present study, we evaluated the efficacy and safety of NBP for the treatment of PCI.Between March 2008 and May 2012, we performed a randomized, double-blind placebo-controlled study including 304 inpatients with PCI. These patients were randomly assigned to the test (152 cases) and control groups (152 cases). The test group received 200 mg of NBP soft capsules orally, 15 minutes before each meal, 3 times daily. The control group received 200 mg of placebo soft capsules orally, 15 minutes before each meal, 3 times daily. Treatment was administered during 21 days. The National Institute of Health Stroke Scale (NIHSS) score was assessed before the treatment and on days 7, 14, 21, and 30 after treatment. The Barthel index (BI) was assessed on the same days and on day 90.In the test group, the NIHSS scores on days 7, 14, 21, and 30 were 14.75 ± 4.85, 11.62 ± 3.49, 8.87 ± 5.17, and 6.38 ± 4.93, respectively. In the control group, they were 16.08 ± 3.76, 13.28 ± 5.02, 11.05 ± 4.25, and 8.43 ± 5.41 (P < .05), respectively. The BI on days 7, 14, 21, 30, and 90 were 51.57 ± 15.11, 61.21 ± 16.39, 70.48 ± 18.21, 76.41 ± 19.02, and 81.10 ± 15.52 for the test group and 46.79 ± 18.42, 55.93 ± 19.12, 64.84 ± 17.67, 70.65 ± 18.54, and 76.54 ± 17.05 for the control group (P < .05), respectively. Adverse events were elevation of alanine aminotransferase and aspartate aminotransferase (P > .05).NBP was useful to improve the outcome of patients with PCI and decreased their disability for activities of daily living. NBP was an efficacious and safe treatment for PCI.
进展性脑梗死(PCI)与高死亡率和高致残率相关。许多研究表明,丁苯酞(NBP)对急性缺血性脑卒中有效。NBP给药可使缺血区域的毛细血管数量增加,促进侧支循环建立,保护线粒体,并缩小梗死面积等。在本研究中,我们评估了NBP治疗PCI的疗效和安全性。
2008年3月至2012年5月,我们进行了一项随机、双盲、安慰剂对照研究,纳入304例PCI住院患者。这些患者被随机分为试验组(152例)和对照组(152例)。试验组在每餐饭前15分钟口服200毫克NBP软胶囊,每日3次。对照组在每餐饭前15分钟口服200毫克安慰剂软胶囊,每日3次。治疗持续21天。在治疗前以及治疗后第7、14、21和30天评估美国国立卫生研究院卒中量表(NIHSS)评分。在相同日期以及第90天评估Barthel指数(BI)。
试验组在第7、14、21和30天的NIHSS评分分别为14.75±4.85、11.62±3.49、8.87±5.17和6.38±4.93。对照组分别为16.08±3.76、13.28±5.02、11.05±4.25和8.43±5.41(P<0.05)。试验组在第7、14、21、30和90天的BI分别为51.57±15.11、61.21±16.39、70.48±18.21、76.41±19.02和81.10±15.52,对照组分别为46.79±18.42、55.93±19.12、64.84±17.67、70.65±18.54和76.54±17.05(P<0.05)。不良事件为丙氨酸转氨酶和天冬氨酸转氨酶升高(P>0.05)。
NBP有助于改善PCI患者的预后并降低其日常生活活动的残疾程度。NBP是一种治疗PCI有效且安全的药物。